# Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

> **NCT05261490** · PHASE1,PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 10 (actual)

## Conditions studied

- Ovarian Cancer
- Ovarian Neoplasms
- Ovarian Carcinoma
- Fallopian Tube Cancer
- Epithelial Ovarian Cancer
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** maplirpacept (PF-07901801)
- **DRUG:** Pegylated Liposomal Doxorubicin (PLD)

## Key facts

- **NCT ID:** NCT05261490
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-01
- **Primary completion:** 2023-10-11
- **Final completion:** 2024-02-15
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study for administrative reasons. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05261490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05261490, "Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05261490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*